Nebius Stock Falls After $3.75 Billion Debt Raise Despite Major AI Deals
Investors weigh dilution concerns as company accelerates data center expansion following Meta and Nvidia partnerships Shares of Nebius (NBIS) dropped ...
Tag: Growth
Airlines Lift Revenue Outlook Despite Rising Fuel Costs
Strong travel demand helps Delta and American offset geopolitical pressures and higher expenses Shares of Delta Air Lines (DAL) and ...
Meta Stock Rises on $27 Billion AI Cloud Deal with Nebius
Massive AI infrastructure push and potential layoffs highlight Big Tech’s shifting priorities Shares of Meta Platforms (META) rose as much ...
BioMarin Halts Mid-Stage Trial of Voxzogo in Certain Bone Disorders
Reports of hip joint complications prompt suspension of studies, sending shares lower Shares of BioMarin Pharmaceutical (BMRN) fell roughly 4% ...
Urgently Shares Surge After Acquisition Announcement and Strong Q4 Results
Agero’s $5.50-per-share offer and better-than-expected earnings drive investor optimism Shares of Urgently (ULY) surged following the company’s announcement that it ...
bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate
Strong commercial adoption of lung cancer diagnostic test fuels investor enthusiasm Shares of bioAffinity Technologies (BIAF) experienced a dramatic rally, ...
Investor Confidence Builds Around CoreWeave and Nebius Amid AI Infrastructure Boom
Strategic partnerships, expanding capacity, and Nvidia backing highlight growing momentum in the neocloud sector Investor confidence is increasing in AI ...
Rivian Unveils R2 Pricing and Trim Levels as It Targets the Mass EV Market
Performance and Premium models arrive first, while the most affordable R2 won’t reach buyers until 2027 Electric vehicle maker Rivian ...
Tilman Fertitta in Exclusive Talks to Acquire Caesars Entertainment
Billionaire restaurateur and casino operator reportedly pursuing $7 billion deal after surpassing rival bid Billionaire entrepreneur Tilman Fertitta is reportedly ...
Acurx Pharmaceuticals Shares Rise on New Clinical Trial Plans
Company advances C. difficile treatment program toward Phase 3 international studies Acurx Pharmaceuticals (ACXP) saw its shares move higher after ...
